medigraphic.com
ISSN 2954-3835 (Electronic)
ISSN 2683-2828 (Print)

2019, Number 3

<< Back Next >>

Cardiovasc Metab Sci 2019; 30 (3)

Joint Mexican Position Document on the Treatment of Atrial Fibrillation

Rodríguez DG, Márquez MF, Iturralde P, Molina L, Pozas G, Cordero CA, Rojel U

Language: English
References: 59
Page: 91-99
PDF size: 224.89 Kb.


Text Extraction

I. What is known about the epidemiology of atrial fibrillation in Mexico? Can it be considered a public health problem?

Atrial fibrillation (AF) incidence and prevalence increase with age. Its prevalence is near to 2% in the general population, but it could be as high as 10% in those over 75 years.1,2 Before the Mexican Registry of Atrial Fibrillation (ReMeFA) was published a market study was conducted in Mexico in 2007, finding that, for a population of 105,338,982 people the prevalence of cardiac arrhythmias was 2.4%, with tachyarrhythmias being the most common with 56% (1,402,453 people), of which, AF was the most frequent arrhythmia, occupying 60.7% of tachycardias (or a total of 851,489 cases).


REFERENCES

  1. Kirchhof P, Benussi S, Koteche D et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962.

  2. Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014; 7: 441-448.

  3. Iturralde TP, Lara VS, Cordero CA et al. Diseño de un registro multicéntrico para evaluar control de ritmo contra control de la frecuencia en fibrilación auricular Registro Mexicano de FA (ReMeFA). Arch Cardiol Mex. 2011; 81 (1): 13-17.

  4. Lara VS, Cordero CA, Martínez FE, Iturralde TP. Registro Mexicano de Fibrilación Auricular (ReMeFA). Gaceta Medica de México. 2014; 150 (1): 48-59.

  5. Cantú-Brito C, Majersik JJ, Sánchez BN et al. Hospitalized stroke surveillance in the community if Durango, México. The Brain Attack Surveillance in Durango Study. Stroke. 2010; 41 (5): 878-884.

  6. Cantú BC, Iturralde TP. Prevención de la EVC. Diagnóstico y tratamiento. México: Ed. Permanyer; 2016. pp. 1-40.

  7. Dell’Orfano J, Patel H, Wolbrette D, Luck J. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol. 1999; 83: 788-790.

  8. Velázquez RE, Cancino R, Arias E, Rangel R. Cardioversión farmacológica con propafenona intravenosa en fibrilación auricular. Arch Cardiol Mex. 2000; 70: 160-166.

  9. Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344: 1411-1420.

  10. Alboni P, Botto G, Baldi N et al. Outpatient treatment of recent onset atrial fibrillation with the “Pill in the Pocket” approach. N Engl J Med. 2004; 351: 2384-2391.

  11. Roden D. Drug induced prolongation of the QT interval. N Engl J Med. 2004; 350: 1013-1022.

  12. Postema P, Wolpert Ch, Amin A et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and up-to-date website. Heart Rhytm. 2009; 6: 1335-1341.

  13. Nair GM, Nery PB, Diwakaramenon S et al. Systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2009; 20: 138-144.

  14. Capucci A, Villani GQ, Aschieri D et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J. 2000; 21: 66-73.

  15. Yu WC, Lin YK, Tai CT et al. Early recurrence of atrial fibrillation after external cardioversion. PACE. 1999; 22: 1614-1619.

  16. De Simone A, De Pasquale M, De Matteis C et al. Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion. Eur Heart J. 2003; 24: 1425-1429.

  17. Mussigbrodt A, John S, Kosiuk J et al. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace. 2016; 18: 51-56.

  18. Gosselink A, Crijns H, Van Gelder I et al. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992; 267: 3289-3293.

  19. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: Executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001; 104 (17): 2118-2150.

  20. Patel C, Salahuddin M, Jones A, Patel A, Yan GX, Kowey PR. Atrial fibrillation: pharmacological therapy. Curr Probl Cardiol. 2011; 36 (3): 87-120.

  21. Parkash R, Tang AS, Sapp JL, Wells G. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol. 2011; 22 (7): 729-738.

  22. Rutzen-Lopez H, Vkhanna V, Reynolds M. Atrial fibrillation: epidemiology, prognosis and therapy. Minerva Med. 2011; 102 (3): 187-207.

  23. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12 (10): 1360-1420.

  24. Kautzner J, Bulkova V, Hindricks G, Maniadakis N, Della Bella P, Jais P et al. Atrial fibrillation ablation: a cost or an investment? Europace. 2011; 13 Suppl 2: II39-43.

  25. Crijns HJ. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs. 2005; 65 (12): 1651-1667.

  26. Cosio FG. Learning by burning in atrial fibrillation: an uncertain, complicated quest. J Cardiovasc Electrophysiol. 2011; 22 (5): 513-515.

  27. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F et al. Catheter ablation of long-lasting persistent atrial fibrillation: Critical structures for termination. J Cardiovasc Electrophysiol. 2005; 16 (11): 1125-1137.

  28. Zhang Y, Mazgalev TN. Ventricular rate control during atrial fibrillation and AV node modifications: Past, present, and future. Pacing Clin Electrophysiol. 2004; 27 (3): 382-393.

  29. Wyse DG, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347 (23): 1825-1833.

  30. Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: targets, methods, resynchronization considerations. Circulation. 2011; 124 (24): 2746-2755.

  31. Carter NJ, Plosker GL. Rivaroxaban: A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs. 2013; 73 (7): 715-739.

  32. Welles CC, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the heart and soul study. Am Heart J. 2011; 162 (3): 555-561.

  33. Lip GYH, Fauchier L, Freedman SB et al. Atrial fibrillation. Nature Reviews Dis Primers. 2016; 2: 1-26.

  34. Pison L, Tilz R, Jalife J, Häissaguerre M. Pulmonary vein triggers, focal sources, rotors and atrial cardiomyopathy: implications for the choice of the most effective ablation therapy. J Intern Med. 2016; 279: 449-456.

  35. Filgueiras-Rama D, Jalife J. Structural and functional bases of cardiac fibrillation. Differences and similarities between atria and ventricles. JACC Clin Electrophysiol. 2016; 2 (1): 1-3.

  36. Goette A, Kalman JM, Aguinaga L et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Europace. 2016; 18 (10): 1455-1490.

  37. Kuck KH, Fürnkranz A, Chun KR et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: Reintervention, rehospitalization and quality of life outcomes in the FIRE and ICE trial. Eur Heart J. 2016; 37 (38): 2858-2865.

  38. Irfan G, de Asmundis C, Mugnai G et al. One-year follow-up after second-generation cryoballoon ablation for atrial fibrillation in a large cohort of patients: a single-centre experience. Europace. 2016; 18 (7): 987-993.

  39. Márquez-Murillo MF, Gómez J, Nava S, Colin L, Iturralde P. Programas de ablación con catéter. Capítulo 8 en Clínicas Mexicanas de Cardiología: Fibrilación auricular. México: Ed. PyDesa; México 2013.

  40. Cárdenas M, Stevens H, Stevens I, Zajarías S. Frecuencia de los accidentes tromboembólicos en cardiopatías con fibrilación auricular con o sin tratamiento anticoagulante. Arch Inst Cardiol México. 1968; 38 (6): 792-799.

  41. Constante-Sotelo JL, Méndez-Domínguez A. Cardiopatía reumática: causa de enfermedad vascular cerebral en el Instituto Nacional de Cardiología Ignacio Chávez. Arch Cardiol Mex. 2006; 76 (1): 47-51.

  42. Wolf PA. Contributions of the Framingham heart study to stroke and dementia epidemiologic research at 60 years. Arch Neurol. 2012; 69 (5): 567-571.

  43. Fauchier L, Philippart R, Clementy N et al. How to define valvular atrial fibrillation? Arch Cardiovasc Dis. 2015; 108 (10): 530-539.

  44. Buen-Abad L, Elizalde-Galván J, Cárdenas M. Prevención a largo plazo de accidentes tromboembólicos con ácido acetilsalicílico en pacientes con fibrilación auricular. Arch Inst Cardiol Mex. 1976; 46 (6): 764-769.

  45. Heras M, Fernández-Ortiz A, Gómez-Guindal J et al. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Rev Esp Cardiol. 1999; 52: 801-820.

  46. De Caterina R, Camm AJ. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace. 2016; 18 (1): 1139-1151.

  47. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016; 9 (2): 182-185.

  48. Ward A, Tompson A, Fitzmaurice D, Sutton S, Perera R, Heneghan C. Cohort study of anticoagulation self-monitoring (CASM): a prospective study of its effectiveness in the community. Br J Gen Pract. 2015; 65 (636): e428-e437.

  49. Escolar-Albaladejo G, Barón-Esquivias G, Zamorano JL et al. Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la prevención del ictus en pacientes con fibrilación auricular no valvular en España. Atención Primaria. 2016; 48 (6): 394-405.

  50. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 (12): 857-867.

  51. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet. 2006; 367 (9526): 1903-1912.

  52. Lip GYH, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010; 41 (12): 2731-2738.

  53. Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013; 143 (1): 179-184.

  54. Vargas RA, Ramírez LA, Medina VM. Nuevos anticoagulantes: dabigatrán, rivaroxabán y apixabán. Gac Med Mex. 2012; 148: 257-268.

  55. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15 (5): 625-651.

  56. De Backer O, Arnous S, Ihlemann N et al. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart. 2014; 1 (1): e000020.

  57. Freeman J V, Hutton DW, Barnes GD et al. Cost-effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL. Circ Arrhythm Electrophysiol. 2016; 9 (6): e003407.

  58. Uslar T, Anabalón J. Is percutaneous closure of the left atrial appendage comparable to anticoagulants for atrial fibrillation? Medwave. 2015; 15 (Suppl. 2): e6218.

  59. Tromboprofilaxis en fibrilación auricular en pacientes mayores de 18 años. Guía de Evidencias y recomendaciones: Guía de Práctica Clínica. México, CENETEC; 2018 [08/07/19]. Disponible en: http://www.cenetec-difusión.com/CMGPC/S-014-18/ER.pdf




2020     |     www.medigraphic.com